Table IV.
Predictive factors for overall survival by univariate and multivariate analyses of the cohort (n = 90)
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Gender: | ||||||
| Female | 1 | – | ||||
| Male | 0.67 | 0.35–1.28 | 0.225 | – | – | – |
| Tumor location: | ||||||
| Rectum | 1 | 1 | ||||
| Colon | 0.55 | 0.29–1.05 | 0.072 | 0.57 | 0.26–1.21 | 0.14 |
| Histologic types: | ||||||
| MAC | 1 | 1 | ||||
| SRC | 2.28 | 1.13–4.59 | 0.022 | 1.58 | 0.71–3.48 | 0.26 |
| Adjuvant CT: | ||||||
| No | 1 | 1 | ||||
| Yes | 0.22 | 0.088–0.53 | 0.001 | 1.29 | 0.27–6.19 | 0.75 |
| Cycles of adjuvant CT: | ||||||
| < 6 | 1 | 1 | ||||
| ≥ 6 | 0.29 | 0.14–0.59 | 0.001 | 0.18 | 0.05–0.62 | 0.007 |
| Tumor size [cm]: | ||||||
| < 5 | 1 | 1 | ||||
| ≥ 5 | 1.89 | 0.98–3.64 | 0.056 | 1.23 | 0.55–2.74 | 0.61 |
| Surgical types: | ||||||
| Radical | 1 | 1 | ||||
| Palliative | 4.41 | 2.31–8.44 | < 0.001 | 1.40 | 0.37–5.28 | 0.62 |
| T stage: | ||||||
| T1/T2 | 1 | |||||
| T3/T4 | 2.70 | 0.37–20.0 | 0.33 | – | ||
| N stage: | – | – | – | |||
| N0 | 1 | 1 | ||||
| N1/2 | 2.65 | 1.03–6.80 | 0.043 | 1.15 | 0.27–4.86 | 0.85 |
| Metastasis: | ||||||
| No | 1 | 1 | ||||
| Yes | 5.15 | 2.65–10.02 | < 0.001 | 1.83 | 0.50–6.64 | 0.36 |
| Stage: | ||||||
| I/II | 1 | 1 | ||||
| III/IV | 4.45 | 1.07–18.5 | 0.04 | 1.84 | 0.26–12.9 | 0.54 |
| Preoperative CEA levels [U/ml]: | ||||||
| < 5 | 1 | 1 | ||||
| ≥ 5 | 3.23 | 1.69–6.17 | < 0.001 | 2.47 | 1.06–5.78 | 0.037 |
| Lymphovascular invasion: | ||||||
| Negative | 1 | 1 | ||||
| Positive | 3.20 | 1.62–6.29 | 0.001 | 1.36 | 0.53–3.47 | 0.52 |
| Perineural invasion: | ||||||
| Negative | 1 | 1 | ||||
| Positive | 1.99 | 1.04–3.81 | 0.038 | 1.38 | 0.53–3.60 | 0.50 |
HR – hazard ratio, CI – confidence interval, MAC – mucinous adenocarcinoma, SRC – signet-ring cell carcinoma, CT – chemotherapy, CEA – carcinoembryonic antigen.